CS-6253 is under clinical development by Artery Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CS-6253’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CS-6253 overview
CS-6253 is under development for the treatment of Alzheimer's disease (AD). Cogpep peptides target ATP-binding cassette transporter A1 (ABCA1). The drug candidates are designed from apolipoprotein E3 (apoE3) to correct the dysfunction caused due to apolipoprotein E4 (ApoE4). It is administered through intravenous route.
Artery Therapeutics overview
Artery Therapeutics is a pre-clinical stage biotechnology company developing effective treatments for neurodegenerative and metabolic diseases. The company pipeline products include ABCA1 transporter, Cogpep, Dipep for the treatment of diabetes-generated cardiovascular disease and neurodegenerative diseases such as alzheimer’s disease, and traumatic brain injury. It works in collaboration with University of Southern California, Tel Aviv University, University of Washington, and Huntington Medical Research Institute providing insights into the interactions among ABCA1, ApoE lipidation and aggregation, stabilizing ABCA1 with CS-6253 to prevent ApoE associated disease. Artery Therapeutics is headquartered in San Francisco, California, the US.
For a complete picture of CS-6253’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
